drugset / Trial / NCT01026363
hCAP18 Levels and Vitamin D Deficiency in Chronic Kidney Disease
Withdrawn
Massachusetts General Hospital
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · collabNational Kidney Foundation, United States · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
The human immune system produces a protein called hCAP18 (also known as LL-37 or cathelicidin). This protein is believed to help the body to fight infections. Studies suggest that vitamin D may important in the production of hCAP18. This study is designed to test the ability of two different forms of vitamin D to affect levels of hCAP18. Vitamin D and hCAP18 levels will be measured during an initial visit. Individuals who are vitamin D deficient will be randomly assigned to receive one of two forms of vitamin D for two weeks. After this, follow-up levels will be measured.
Timeline
- Start
- 2009-12
- Primary completion
- 2014-07
- Completion
- 2014-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Calcitriol | Small molecule | 0.25 ug | — |
| Subject | Ergocalciferol | Small molecule | 50000 iu | — |